Emergent BioSolutions | EBS - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 279.64M 36.37M 2026-06
Akebia Therapeutics USD 47.28M 1.7M 2025-12
ALKERMES USD 375.31M 43.98M 2026-06
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Amarin USD 23.17M 961K 2025-12
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Coherus Biosciences USD 8.7M 853K 2025-12
Exelixis USD 590.86M 18.68M 2026-03
Glaxosmithkline GBP 5.75B 2.99B 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 265M 22M 2026-06
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
Lonza CHF 1.29B 248M 2025-06
Merck USD 12.09B 1.24B 2026-03
Moderna USD -566M 792M 2026-03
Myriad Genetics USD 146.8M 3M 2025-12
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Pacira USD 133.91M 7.27M 2026-06
Pfizer USD -248M 11.29B 2026-06
PTC Therapeutics USD 232.94M 84.56M 2026-03
Sanofi EUR 8.71B 602M 2026-06
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12